Mutations in factor H (CFH), factor I (IF), and membrane cofactor protein (MCP) genes have
been described as risk factors for atypical hemolytic uremic syndrome (aHUS). This study …

Background Mutations in complement factor H (CFH), factor I (CFI), factor B (CFB),
thrombomodulin (THBD), C3 and membrane cofactor protein (MCP), and autoantibodies …

Mutations in the plasma complement regulator factor H (CFH) and the transmembrane
complement regulator membrane co-factor protein (MCP) have been shown to predispose to …

Over the past decade, atypical hemolytic uremic syndrome (aHUS) has been demonstrated
to be a disorder of the regulation of the complement alternative pathway. Among …

Several abnormalities in complement genes reportedly contribute to atypical hemolytic
uremic syndrome (aHUS), but incomplete penetrance suggests that additional factors are …

Genetic studies have shown that mutations of complement inhibitors such as membrane
cofactor protein, Factors H, I, or B and C3 predispose patients to atypical hemolytic uremic …

Central to the pathogenesis of atypical hemolytic uremic syndrome (aHUS) is over-activation
of the alternative pathway of complement. Following the initial discovery of mutations in the …

Atypical hemolytic uremic syndrome is often associated with mutations in genes encoding
complement regulatory proteins and secondary disorders of complement regulation …

Results Onset of aHUS occurred as frequently during adulthood (58.4%) as during
childhood (41.6%). The percentages of patients who developed the disease were 23 …

Atypical hemolytic and uremic syndrome (aHUS) is a severe disease strongly associated
with genetic abnormalities in the complement alternative pathway. In renal …